Regeneron Posts Strong Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its fourth-quarter earnings, which exceeded expectations.

For the fourth quarter, Regeneron reported an adjusted earnings per share (EPS) of $11.86, surpassing the consensus estimate of $10.62. The company's revenue for the quarter was $3.43 billion, exceeding analysts' expectations of $3.27 billion.

Eylea net sales for the company amounted to $1.34 billion, which did not meet the anticipated $1.46 billion by Wall Street. However, Dupixent net sales were $2.49 billion, slightly exceeding the forecast of $2.47 billion.
Regeneron Pharmaceuticals, Inc. View
Symbol Price %chg
207940.KS 781000 -1.28
068270.KS 189700 -2.58
028300.KQ 105600 -1.23
196170.KQ 169900 -2.47
REGN Ratings Summary
REGN Quant Ranking
Related Analysis